EyePoint Pharmaceuticals Q2 EPS $(1.09) Misses $(0.95) Estimate, Sales $507.000K Beat $406.857K Estimate
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.95) by 14.74 percent. This is a 28.24 percent decrease over losses of $(0.85) per
EyePoint Pharmaceuticals lost more money per share than experts predicted, even though their sales were stronger than expected. When a company loses more money than people thought, it suggests the business is spending faster than it's earning, which is worth watching.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.